Figures for the number of trials for Phase I clinical research clearly shows a continuing and relatively strong performance by the UK. Although the US is way out ahead of all other countries, the UK performs strongly, leading the remainder of the peer group (a sample of other countries within and outside the EU comparable to the UK). There is a slight decline in 2016 for the UK, which relate to changes in clinical design or stages of pipeline development, but any real interpretation of trends should be reviewed over a longer time period.
Only commercial trials related to pharmaceutical drug development and molecular/biological entities were included. Collaborative trials were only included if one or more partners were a commercial organisation and all therapeutic areas were included in this analysis.